TY - JOUR T1 - A Case of Recurrent Metastatic Parotid Acinic Cell Carcinoma Responsive to Pembrolizumab JF - In Vivo JO - In Vivo SP - 1047 LP - 1051 DO - 10.21873/invivo.12801 VL - 36 IS - 2 AU - GAI YAMASHITA AU - ISAKU OKAMOTO AU - AKIRA SHIMIZU AU - KUNIHIKO TOKASHIKI AU - TAKURO OKADA AU - HIROKI SATO AU - KIYOAKI TSUKAHARA Y1 - 2022/03/01 UR - http://iv.iiarjournals.org/content/36/2/1047.abstract N2 - Background: No clear chemotherapy regimen for recurrent or metastatic parotid cancer exists. We describe our experience with pembrolizumab to treat recurrent or metastatic parotid cancer. Case Report: A 73-year-old woman with swelling in the lower part of the right ear for 10 years before surgery was diagnosed with right parotid cancer, underwent total right parotidectomy, and reported recurrence. She requested treatment due to diminished quality of life caused by neurological symptoms. Tissue was collected from the recurrent lesion and its combined positive score was >20; pembrolizumab was started 9 years postoperatively. Results: To date, the patient has received 14 cycles of pembrolizumab. Evaluation by computed tomography showed a partial response to treatment. The only immune-related adverse event was grade 1 pneumonia in both lungs. Conclusion: Significant response to pembrolizumab in recurrent or metastatic parotid cancer is rarely reported, making this a remarkable case. We plan to continue pembrolizumab administration. ER -